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Abstract
Related Transcriptional Enhancer Factor-1 (RTEF-1) has been suggested to induce angiogenesis through regulating target
genes. Whether RTEF-1 has a direct role in angiogenesis and what specific genes are involved in RTEF-1 driven angiogenisis
have not been elucidated. We found that over-expressing RTEF-1 in Human dermal microvascular endothelial cells-1 (HMEC-
1) significantly increased endothelial cell aggregation, growth and migration while the processes were inhibited by siRNA of
RTEF-1. In addition, we observed that Endothelial differentiation gene-1 (Edg-1) expression was up-regulated by RTEF-1 at
the transcriptional level. RTEF-1 could bind to Edg-1 promoter and subsequently induce its activity. Edg-1 siRNA significantly
blocked RTEF-1-driven increases in endothelial cell aggregation in a Matrigel assay and retarded RTEF-1-induced endothelial
cell growth and migration. Pertussis Toxin (PTX), a Gi/Go protein sensitive inhibitor, was found to inhibit RTEF-1 driven
endothelial cell aggregation and migration. Our data demonstrates that Edg-1 is a potential target gene of RTEF-1 and is
involved in RTEF-1-induced angiogenesis in endothelial cells. Gi/Go protein coupled receptor pathway plays a role in RTEF-1
driven angiogenesis in endothelial cells.
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Introduction
Related Transcriptional Enhancer Factor 1 (RTEF-1), also
known as TEAD4 (TEA domain family member 4), is a member of
the Transcription Enhancer Factor family, and plays important
roles in a variety of physiological and pathological conditions.
RTEF-1 targets the promoters of many genes and shares a highly
conserved domain capable of binding to the MCAT element
CATN(T/C)(T/C) [1,2] in the promoter region of genes
expressed in endothelial [3], cardiac [4], skeletal and smooth
muscle cells [5], as well as myofibroblasts [6]. In endothelial cells,
RTEF-1 is involved in the stimulation of angiogenesis under
hypoxia via transcriptional regulation of its target genes [7].
RTEF-1 is shown to transcriptionally regulate Hypoxia inducible
factor (HIF)-1 and accelerate recovery rates from hind limb
ischemic injury [3]. In addition, RTEF-1 impacts the Fibroblast
growth factor (FGF)/FGFR system through the eNOS pathway in
the regulation of angiogenesis and vasodilation [8]. We have
recently found that endothelial specific RTEF-1-deficient mice
lack the ability to form normal capillary networks suggesting that a
loss of RTEF-1 signaling leads to the disintegration of the mature
vasculature and that RTEF-1 is required for endothelial connec-
tions and capillary network formation [9]. However, the direct
effect of RTEF-1 on angiogenesis in endothelial cells and new
target genes that might be involved in RTEF-1 driven angiogen-
esis has not been fully understood.
Endothelial differentiation gene 1 (Edg-1), also known as
sphingosine-1-phosphate receptor 1 (S1PR1 or S1P1) is a G-
protein-coupled receptor. It binds the ligand sphingosine-1-
phosphate (S1P) with high affinity and high specificity and is
suggested to be involved in the processes that regulate the
differentiation of endothelial cells. Activation of this receptor by
S1P induces cell–cell adhesion [10], migration and proliferation in
endothelial cells [11]. Edg-1
2/2 mice exhibit embryonic hemor-
rhage leading to intrauterine death between E12.5 and E14.5 due
to a deficiency in vascular maturation [12]. These findings suggest
that Edg-1 plays an important role in angiogenesis. However,
transcription factors that regulate Edg-1 in angiogenesis have not
been elucidated.
Here, we report that the transcription factor RTEF-1 is
involved in enhancing angiogenesis in endothelial cells. Further-
more, we show that RTEF-1 regulates Edg-1 gene expression as a
transcriptional activator upon binding to Edg-1 promoter. In
addition, the angiogenesis enhanced by RTEF-1 is associated with
the Edg-1 and Pertussis Toxin (PTX)-sensitive Gi/Go protein
pathway.
Materials and Methods
Ethics Statement
The animal study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e88143Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at Beth Israel Deaconess Medical Center (049-2011).
Cell Culture
Human dermal microvascular endothelial cells-1 (HMEC-1;
Center of Disease Control) were cultured in MCDB-131
(Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum,
10 ng/ml epidermal growth factor, 1 mg/ml hydrocortisone and
2 mM L-glutamine. HEK293 (human embryonic kidney 293;
ATCC) and HEK293T (a derivative of HEK293 which constitu-
tively expresses the simian virus 40 large T antigen; ATCC) cells
were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen,
Carlsbad, CA) with 10% fetal bovine serum.
Generation of RTEF-1 Transgenic Mice
RTEF-1 transgenic mice were generated at the BIDMC
Transgenic Core Facility using the vascular endothelial (VE)-
cadherin promoter to drive endothelial-specific expression of
human RTEF-1 [13]. RTEF-1 transgenic mice were genotyped by
PCR as described previously [14]. A conditional knockout (KO)
line of RTEF-1 was generated by crossing homozygous TEA-
D4lox/lox mice (a gift from Dr. Andres Buonanno, NICHHD,
NIH) with transgenic mice expressing Cre recombinase under
control of the endothelial cell-specific Tie2 promoter/enhancer (a
gift from Dr. Anthony Rosenzweig, BIDMC) [15]. Mice were
screened by PCR to verify germline transmission, using primers
P1, P2, P3 and/or P4 as described previously [16].
Retroviral Transduction
The stable over-expression of RTEF-1 in HMEC-1 cells was
performed as previously described [3]. In brief, the coding
sequence of RTEF-1 (NM_003213) was subcloned into the
pBMN-GFP vector (Orbigen, San Diego, CA). In 10-cm dishes,
6610
6 HEK293T cells were transfected with pBMN-GFP-RTEF-
1, pMD-VSVG, pJK3, or pCMV-tat using Polyethyleneimine
(Polysciences, Warrington, PA). After 48 hours transfection, virus-
containing medium was collected, filtered through a 0.45-mm
filter, and used as a transducer for HMEC-1 cells. After
transfection, cells were selected with puromycin (250 ng/ml).
Small Interfering RNA Transfection
Small interfering RNA (siRNA) encoding human RTEF-1 or
Edg-1 (Genpharma Shanghai, China) at a final concentration of
50 nM was transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) and confirmed by real- time PCR and western
blotting. Two duplexes of RTEF-1 siRNA (59-GGG CAG ACC
UCA ACA CCA ATT-39,5 9-UUG GUG UUG AGG UCU
GCC CAG-39 and 59- ACC CAA GAU GCU GUG UAU UTT-
39,5 9- AAU ACA CAG CAU CUU GGG UTT-39) and two
duplexes of Edg-1 siRNA (59- GCU AUA UCA CAA UGC UGA
ATT, 59- UUC AGC AUU GUG AUA UAG CTT-39 and 59-
GCC CAC UUU AUC UAA AUG ATT-39,5 9- UCA UUU
AGA UAA AGU GGG CTT-39) were used in the experiment. A
duplex of RNA(59- UUC UCC GAA CGU GUC ACG UTT-39,
59- ACG UGA CAC GUU CGG AGA ATT-39) that is not
targeted to any human gene was used as a negative control.
Briefly, a master mix of Lipofectamine 2000 was diluted with 1 ml
of OPTI-MEM (Invitrogen, Carlsbad, CA) and incubated for
5 min. The Lipofectamine 2000 dilution was added to the siRNA
dilution, incubated for 20 min, and added drop-wise to the cells.
Five hours after transfection, medium was changed and the cells
were allowed to recover overnight. Forty-eight hours after
transfection, cells were harvested for mRNA and protein
dectection or followed by Matrigel, migration and cell growth
assays as designed.
RNA and Protein Analyses
Total RNA was extracted from cells or lungs of mice that were
euthanized by carbon dioxide. A total of 2.0 mg of RNA was
reverse-transcribed using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Carlsbad, CA) with random
primers according to the manufacturer’s protocol. Quantitative
real-time PCR amplification was done using SYBR Green Master
Mix (Applied Biosystems, Carlsbad, CA) according to the
manufacturer’s instruction. Gene expression was analyzed with
the primers for Edg-1 (59- CTCCACAACGGGAGCAATAAC-39
and 59- CAGCGCACTGATGCAGTTC-39), RTEF-1 (59-
CCACGAAGGTCTGCTCTTTC-39 and 59-CTCACTGGCT-
GACACCTCAA-39) and Actin (59- TCTTTAATGTCACG-
CACGATT-39 and 59- TCACCCACACTGTGCCCAT-39).
Proteins were isolated from cells or tissue samples lysed in cold
RIPA buffer (Boston BioProducts, Worcester, MA) supplemented
with a cocktail of protease inhibitors (Roche Applied Science,
Branford, CT). Protein concentration was determined with the
DC Protein Standard Assay (Bio-Rad, Hercules, CA). Samples
were subjected to 10–12% SDS-PAGE, transferred to polyviny-
lidene fluoride membranes (Millipore, Billerica, MA) and subse-
quently blocked in Tris-buffered saline-Tween 20 containing 8%
nonfat milk. The membranes were then incubated with the
indicated primary antibodies: anti-Edg-1 (NOVUS Biologicals,
Littleton, CO, 1:1000), anti-RTEF-1 (Genemed Synthesis Inc, San
Antonio, TX; 1:10,000) and anti-Vinculin (Sigma-Aldrich, St.
Louis, MO; 1:100,000), respectively, followed by incubation with
horseradish peroxidase-conjugated secondary antibodies anti-
rabbit IgG with 1:3000 dilution (Calbiochem, La Jolla, CA) or
anti-mouse IgG with 1:2000 dilution (Vector Labs, Burlingame,
CA). Blots were developed using the chemiluminescence detection
system according to the instructions of the manufacturer (Thermo
Fisher, Pittsburgh, PA).
Matrigel Analysis
Growth Factor-Reduced BD Matrigel Matrix (BD Biosciences,
San Jose, CA) was coated on a pre-chilled 24-well culture plate on
ice. After Matrigel solidification for 30 minutes, RTEF-1 over-
expression (RTEF-1 o/e) HMEC-1 and pBMN-GFP over-expres-
sion (control) HMEC-1 cells were plated at 10
5 cells per well. The
extent of network formation was observed and photographed at
6 h and 24 h of culture in Matrigel. In a second set of
experiments, RTEF-1 siRNA or corresponding negative control
siRNA (50 nmol/ml each) transfected control HMEC-1 cells and
Edg-1 siRNA or corresponding negative control siRNA (50 nmol/
ml each) transfected RTEF-1 o/e HMEC-1 cells and control
HMEC-1 cells were plated in Matrigel and the capillary network
was observed at 24 h. In a tertiary experiment, the capillary
network formation was tracked at 24 h Matrigel in RTEF-1 o/e
HMEC-1 or control HMEC-1 with or without PTX (200 ng/mL,
Tocris Biosciences, Minneapolis, MN) treatment. Tubule length
ratio, branch number per field and aggregation area were
analyzed using Image J software.
Migration Analysis
Cell migration in RTEF-1 siRNA (50 nmol/ml) treated control
HMEC-1 cells and Edg-1 siRNA (50 nmol/ml) treated RTEF-
1 o/e HMEC-1 cells and control HMEC-1 cells were compared to
their corresponding negative siRNA transfected controls. The
comparison was also performed in RTEF-1 o/e HMEC-1 cells
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PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e88143Figure 1. RTEF-1 induces angiogenesis in endothelial cells. A. RTEF-1 was over-expressed in HMEC-1. RTEF-1 mRNA (left) and protein (right)
were detected in control HMEC-1 and RTEF-1 o/e HMEC-1. (**=p,0.01, vs control HMEC-1) B. RTEF-1 expression was knocked down by RTEF-1 siRNA
in control HMEC-1. (**=p,0.01, vs control HMEC-1; left: mRNA; right: protein) C. RTEF-1 enhanced endothelial cell connections. The tubule length
(left) and branch number (middle) were increased by RTEF-1 at 6 h in Matrigel compared to control. Notably, tube formation was more apparent at
24 h than at 6 h in Matrigel. The aggregation area (right) were increased by RTEF-1 both at 6 h and 24 h in Matrigel and pronounced at 24 h in
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mL). The cell migration rate was measured using the wound
healing assay. Briefly, equal numbers (1610
5) of RTEF-1 o/e
HMEC-1 and control HMEC-1 cells were plated in 12-well plates
and serum-starved in 0.5% serum medium for 24 hours. The
monolayer of cells was wounded by manual scratching with a
200 ml pipette tip and the cells were then cultured in complete
growth medium. Matched wound regions were photographed with
a Nikon microscope using phase contrast at 0 h and 12 h
migration. The migration rate was assessed by the quotient of
the cell migration distance divided by the original scratched width.
Cell Growth Assay
Crystal violet assay was used to detect cell growth. A total of 10
4
cells of control HMEC-1 and RTEF-1 o/e HMEC-1 treated with
or without RTEF-1 siRNA (50 nmol/ml) and Edg-1 siRNA
(50 nmol/ml) were plated in each well of a 24-well plate. At 5 h
and on 2, 3, and 4 days after plating, cells were fixed in 100%
ethanol and subsequently stained with 0.1% crystal violet dissolved
in 10% ethanol. After staining and thorough washing, the dye was
extracted with 10% acetic acid, and absorbance was measured at
590 nm.
Immunofluorescence
Lungs were removed from transgenic and littermate control
mice euthanized by carbon dioxide, embedded in O.C.T.
compound (Sakura Finetek USA Inc., Torrance, CA), and frozen
at 280uC. Tissues were sectioned with a Cryostat CM Model
3050S-3-1-1 (Leica, Wetzlar, Germany), fixed in 4% paraformal-
dehyde, and stained with antibodies against Edg-1 (Novus
Biologicals, Littleton, CO) with a 1:1000 dilution and Lectin
(Sigma-Aldrich, St. Louis, MO) with a 1:500 dilution followed by
incubation with goat anti-rabbit TRITC and FITC antibody
(Santa Cruz, Santa Cruz, CA) at a dilution of 1:500. Immuno-
fluorescence-stained sections were visualized with a DM5000B
upright microscope (Leica, Wetzlar, Germany).
Promoter Activity and Chromatin Immunoprecipitation
(ChIP)
A construct containing nucleotide fragment (2831 bp to 174 bp
of human sequence at GeneBank: NM_001400.4) encompassing
basal elements of the human Edg-1 promoter was obtained from
Switchgear Genomics (Menolo Park, CA). HEK293 cells were
transfected with the construct and different doses of pXJ40/
RTEF-1 and pXJ40 (gifted from Dr. Alexandre Stewart,
University of Ottawa) using Polyethyleneimine. The addition of
pXJ40 was used to maintain the same cDNA background.
Luciferase activity was determined using the dual luciferase assay
system (Switchgear Genomics, Menolo Park, CA) 24 hours after
transfection. Chromatin immunoprecipitation was performed with
the ChIP-IT Express Kit (Active Motif, Carlsbad, CA) according
to the manufacturer’s instructions. The Edg-1 and Actin
promoters were amplified with the primer pairs 59-AAA CCC
CTC GCC CAA CAC CAA-39,5 9-GCG AGA GGT ACG GAG
GAG ACA AGC-39, and 59- TCT TTA ATG TCA CGC ACG
ATT-39,5 9- TCA CCC ACA CTG TGC CCA T-39, respectively.
Edg-1 primers were designed to the putative MCAT element
binding site for RTEF-1 and the amplification sequence was 2
595 bp to 2418 bp from the transcription start site.
Statistical Analysis
Results are expressed as the mean value6SD. Student’s t test
was used for two samples test and multiple comparisons among
three or more groups were carried out by one-way ANOVA. A
value of P,0.05 was considered significant.
Results
RTEF-1 Promotes Endothelial Cell Aggregation, Migration
and Cell Growth
To determine the direct effect of RTEF-1 on angiogenesis in
endothelial cells, we constructed the stable over-expressing RTEF-
1 (RTEF-1 o/e) HMEC-1 (Figure 1A) and the transient RTEF-1
siRNA-transfected HMEC-1 (Figure 1B). In the Matrigel assay,
RTEF-1 o/e HMEC-1 cells showed a significant cell aggregation
both at 6 h and 24 h and tube formation mostly at 6 h (Figure 1C)
while RTEF-1 siRNA-transfected HMEC-1s in which endogenous
RTEF-1 was knocked down attenuated the formation of normal
capillary network at 24 h (Figure 1D). In addition, RTEF-1 o/e
HMEC-1 demonstrated a rapid migration in the scratch assay
(Figure 1E) and a rising cell growth in the crystal violet assay
(Figure 1G) whereas RTEF-1 siRNA retarded endothelial cell
migration (Figure 1F) and growth (Figure 1H). The observation
indicated that RTEF-1 promotes angiogenesis in endothelial cells.
RTEF-1 Regulates Edg-1 Gene Expression in vitro and
in vivo
In a DNA microarray data from human umbilical vein
endothelial cells (HUVEC), we found that Edg-1 was significantly
down-regulated following RTEF-1 knockdown by RTEF-1 siRNA
(p=0.0002, vs negative control siRNA treated HUVEC) (Figure
S1). To test our hypothesis that Edg-1 might be a potential target
gene of RTEF-1, RTEF-1o/e HMEC-1 as well as RTEF-1
knockdown HMEC-1 by RTEF-1 siRNA was examined for Edg-1
expression. Edg-1 mRNA increased to 1.80 fold in RTEF-1o/e
HMEC-1 cells and decreased to 0.13 fold and 0.30 fold in RTEF-1
knockdown HMEC-1 cells compared to their corresponding
controls (Figure 2A). Edg-1 protein expression in HMEC-1 cells
with or without RTEF-1 showed a similar trend to that of Edg-
1 mRNA (Figure 2B). Moreover, expression of Edg-1 in lung tissue
dramatically increased in VE-Cad: RTEF-1 mice and decreased in
RTEF-1
2/2 mice compared to their littermate controls (mRNA
expression shown in Figures 2C and protein expression shown in
2D). We further confirmed that Edg-1 was localized in the
endothelium by co-staining with antibodies against CD31 and
Edg-1 in the lungs of control and transgenic mice (Figures 2E) and
the expression of Edg-1 was apparently associated with the RTEF-
1 gene level in these mice.
To determine whether Edg-1 is regulated by RTEF-1 on a
transcriptional level, the Edg-1 promoter was co-transfected with
Matrigel. (*=p,0.05, vs control 6 h HMEC-1; **=p,0.01, vs control 6 h HMEC-1; DD=p,0.01, vs RTEF-1 o/e 6 h Matrigel; ##=p,0.01, vs control
24 h HMEC-1; Triangle: aggregation area; Arrow: branch) D. RTEF-1 siRNA decreased endothelial cell connections. The tubule length (left), branch
number (middle) and aggregation area (right) in Matrigel assay were significantly lowered by RTEF-1 siRNA. (*=p,0.05, vs negative control siRNA;
Triangle: aggregation area; Arrow: branch) E. RTEF-1 increased endothelial cell migration. (**=p,0.01, vs control HMEC-1) F. RTEF-1 siRNA retarded
endothelial cell migration. (*=p,0.05, vs control HMEC-1) G. RTEF-1 increased endothelial cell growth. (*=p,0.05, vs control HMEC-1; **=p,0.01,
vs control HMEC-1) H. RTEF-1 siRNA inhibited endothelial cell growth (**=p,0.01, vs control HMEC-1). The results were quantified based on three
independent experiments and are presented as mean6S.D.
doi:10.1371/journal.pone.0088143.g001
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promoter exhibited an increased activity in an RTEF-1 dose-
dependent manner, with a maximum 4.0 fold enhancement
(Figure 2F). The physical interaction of RTEF-1 with the Edg-1
promoter was examined by ChIP assay in RTEF-1 o/e HMEC-1.
As shown in Figure 2G, a specific DNA fragment was detected in
RTEF-1 immunoprecipitated chromatin. Together, these data
indicated that RTEF-1 up-regulated Edg-1 expression in endo-
thelial cells by binding with Edg-1 promoter and increasing Edg-1
promoter activity.
Edg-1 Takes Part in RTEF-1-driven Endothelial Cell
Aggregation, Migration and Growth
To determine whether Edg-1 is involved in RTEF-1 induced
angiogenesis in endothelial cells, we transiently transfected Edg-1
siRNA into RTEF-1 o/e HMEC-1 and control HMEC-1 and
observed endothelial cell aggregation, migration and growth. As
shown in Figure 3B, Edg-1 siRNA significantly decreased the
aggregation area both in RTEF-1 o/e HMEC-1 and control
HMEC-1, while the inhibitory effect on tube formation was
obvious in control HMEC-1 but not in RTEF-1 o/e HMEC-1.
Knockdown of Edg-1 also retarded cell migration in both RTEF-
1 o/e HMEC-1 and control HMEC-1 compared with negative
control siRNA (Figure 3C). Crystal violet assay demonstrated that
RTEF-1 o/e HMEC-1 cell growth had been inhibited by Edg-1
siRNA after culture for 2 days (Figure 3D). These results showed
that Edg-1 participates in RTEF-1 stimulated angiogenesis in
endothelial cells.
PTX Inhibited RTEF-1 Driven Endothelial Cell Tube
Formation and Migration
To further confirm that the Edg-1 post-receptor signaling
pathway plays a role in RTEF-1 stimulated endothelial angiogen-
esis, RTEF-1 o/e HMEC-1 and control HMEC-1 cells were
treated with or without PTX, a Gi/Go protein inhibitor. The
result showed that PTX had an obvious inhibitory effect on tube
formation and aggregation in both RTEF-1 o/e HMEC-1 and
control HMEC-1 at 6 h and 24 h Matrigel (Figure 4A). Further-
more, treatment with PTX showed a significant retardation of
migration in RTEF-1 o/e HMEC-1 and control HMEC-1
(Figure 4B).
Discussion
Angiogenesis is the physiological process through which new
blood vessels form from pre-existing vessels. Sprout angiogenesis
generates from the activation of endothelial cells by angiogenic
growth factors. The activated endothelial cells proliferate into the
surrounding matrix and form solid sprouts connecting neighboring
vessels. After that, endothelial cells migrate in tandem and form
loops to become a full-fledged vessel lumen. An increase in
capillary network formation, endothelial cell proliferation and
migration are the most important features of angiogenesis. We
have observed an increase capillary formation at quadriceps [3]
and heart [14] in VE-Cad/RTEF-1 mice compared with wild type
mice in our previous work. It demonstrates that RTEF-1 has a
proangiogenesis effect in vivo. In this study we found that stable
over-expression of RTEF-1 cDNA in endothelial cells enhanced
cell growth, migration and capillary network formation, while
knockdown of RTEF-1 by its siRNA slowed down these processes
of angiogenesis. These data indicate that RTEF-1 plays an
important role in angiogenesis by activating endothelial cells
in vitro.
Downstream genes such as VEGF and Cx43 have been
suggested to be involved in RTEF-1 induced angiogenesis [7,9]
and Cx43 has been revealed to involve in RTEF-1-enhanced
endothelial cell connections. Quantitative real-time PCR detection
showed that RTEF-1 over-experssion increased Cx43 mRNA in
HMEC-1 cells at Matrigel. The enhancing effect of RTEF-1 on
Cx43 gene expression in Matrigel was observed distinct at 6 h and
fell off at 24 h (Figure S2A). However, RTEF-1 over-expression
showed an apparent increasing in stimulating endothelial cell tube
formation and aggregation in Matrigel at 24 h compared to 6 h
(Figure 1C). It indicated that there might be some new genes play
a role in this context. Edg-1 has been reported to enhance
endothelial cell and vascular smooth muscle cell proliferation and
migration and plays a key role in developmental and pathological
angiogenesis [17]. Interestingly, we found that Edg-1 mRNA was
in a higher level in RTEF-1 o/e HMEC-1 at 24 h Matrigel than
at 6 h Matrigel (Figure S2B). Moreover, our data revealed with
convincing evidence, that Edg-1 is a target gene of RTEF-1. First,
stable over-expression of RTEF-1 cDNA in endothelial cells and
transgenic over-expression of RTEF-1 in mice endothelium led to
an increase in Edg-1 mRNA and protein levels, while knockdown
of RTEF-1 expression by siRNA and endothelial-specific knockout
of RTEF-1 in mice caused a decrease in Edg-1 gene expression
levels. Second, Edg-1 was detected to be co-localized with RTEF-1
in endothelial cells in vivo. Third, RTEF-1 demonstrated a
significant dose-dependent stimulating effect on the Edg-1
promoter upon binding to it. The evidence indicates that Edg-1
is a downstream target gene of RTEF-1.
Whether Edg-1 takes part in RTEF-1-enhanced angiogenesis in
endothelial cells is largely unknown. In the current study, we
evaluated the effect of Edg-1 on RTEF-1-related endothelial
capillary network formation, cell growth and migration. Our data
showed that knockdown of Edg-1 expression by its siRNA
attenuated the stimulating effect of RTEF-1 on endothelial cell
growth, migration and aggregation. Although Edg-1 siRNA did
not produce a decreasing tube formation in RTEF-1 o/e HMEC-
1, it inhibited tube formation in control HMEC-1. It revealed that
knockdown of Edg-1 by siRNA could retard the effect of
endogenous RTEF-1 but cannot overcome the over-expression
of RTEF-1. As a receptor, the activation or inactivation of Edg-1
might play a more important role in receptor function than
expression changes of the receptor itself. Therefore, whether Edg-
Figure 2. Edg-1 is a potential target gene of RTEF-1 in vitro and in vivo.A .Edg-1 mRNA levels were significantly increased in RTEF-1 o/e
HMEC-1 and decreased in RTEF-1 knockdown control HMEC-1. (*=p,0.05; **=p,0.01, vs control HMEC-1) B. Edg-1 protein levels showed similar
results to mRNA levels when RTEF-1 was over-expressed (left panel) or knocked down (right panel). C. Edg-1 mRNA expression level in the lung was
increased in VE-Cad: RTEF-1 mice and decreased in RTEF-1
2/2 mice (*=p,0.05; **=p,0.01, vs control mice). D. Immunoblot analysis of lungs from
both VE- Cad: RTEF-1 mice and RTEF-1
2/2 mice. VE-Cad: RTEF-1 mice showed an increase in Edg-1 expression, while RTEF-1
2/2 mice showed a
decrease in Edg-1 expression when compared to their littermate controls. E. Lung tissues from VE-Cad: RTEF-1 mice, RTEF-1
2/2 mice and their
littermate controls were stained with anti-Edg-1 and anti-CD31 antibodies. F. Edg-1 full length promoter was transiently co-transfected with different
concentrations of RTEF-1, and luciferase activity was examined. Edg-1 promoter activity was shown to be up-regulated in an RTEF-1 dose-dependent
manner. (*=p,0.05; **=p,0.01). G. ChIP assays were performed by immunoprecipitating chromatin from HMEC-1 cells with control IgG or anti-
RTEF-1 antibody and followed by RT-PCR. The results were quantified from three independent experiments and are presented as mean6S.D.
doi:10.1371/journal.pone.0088143.g002
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PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e881431 receptor coupled pathways are involved in RTEF-1 driven
angiogenesis is needed to be clarified.
Previous investigation revealed that Edg-1 coupled with
members of the Gi family (sensitive to PTX) but not Gs, Gq, or
G12/13 (insensitive to PTX) [18]. Observations also found that
PTX suppressed endothelial cell DNA synthesis and migration in
response to S1P, a specific ligand of Edg-1. It suggested that the
activated Edg-1 function is mediated through PTX-sensitive Gi/
Go –proteins [11]. Our results showed that PTX interrupted
RTEF-1 o/e HMEC-1 capillary network formation and migra-
tion, indicating that PTX-sensitive Gi/Go -proteins coupled with
the Edg-1 pathway are involved in RTEF-1 driven angiogenesis in
endothelial cells.
In summary, we have shown for the first time that RTEF-1
binds to the Edg-1 promoter in mature endothelial cells, induces
Edg-1 transcription, and is required for endothelial angiogenesis.
Edg-1 is a new target gene of RTEF-1 involved in angiogenesis.
Furthermore, PTX-sensitive Gi/Go -protein pathway coupled
with Edg-1 was discovered to play an important role in RTEF-1
driven angiogenesis in endothelial cells. These findings would be
helpful to elucidate the role of RTEF-1 as a transcription factor in
angiogenesis and have important potential in development of
Figure 3. Edg-1 is involved in RTEF-1 driven angiogenesis in endothelial cells. A. Edg-1 expression was knocked down by Edg-1 siRNA.
(**=p,0.01, vs control siRNA treated RTEF-1 o/e HMEC-1) B. Edg-1 siRNA inhibited RTEF-1 driven endothelial cell aggregation. (#=p,0.05, vs
negative control siRNA treated control HMEC-1; **=p,0.01, vs negative control siRNA treated RTEF-1 o/e HMEC-1; ##=p,0.01, vs negative control
siRNA treated control HMEC-1; Triangle: aggregation area; Arrow: branch) C. Edg-1 siRNA inhibited RTEF-1 driven endothelial cell migration. (#=p,
0.05, vs negative control siRNA treated control HMEC-1; *=p,0.05, vs negative control siRNA treated RTEF-1 o/e HMEC-1) D. Treatment with Edg-1
siRNA attenuated cell growth in RTEF-1 o/e HMEC-1 (*=p,0.05; **=p,0.01, vs negative control siRNA). The results were quantified based on three
experiments and are presented as mean6S.D.
doi:10.1371/journal.pone.0088143.g003
Figure 4. PTX inhibits RTEF-1 driven endothelial cell aggregation and migration. A. PTX decreased RTEF-1 driven endothelial cell tube
formation and aggregation. (D=p,0.05, vs control HMEC-1 at 6 h Matrigel; *=p,0.05, vs RTEF-1 o/e HMEC-1 at 6 h Matrigel; **=p,0.01, vs RTEF-
1 o/e HMEC-1 at 6 h Matrigel; 1=p,0.05, vs control HMEC-1 at 24 h Matrigel; 11=p,0.01, vs control HMEC-1 at 24 h Matrigel; ##=p,0.01, vs
RTEF-1 o/e HMEC-1 at 24 h Matrigel; Triangle: aggregation area; Arrow: branch) B. PTX retarded RTEF-1 driven endothelial cell migration (#=p,0.05,
vs control HMEC-1 without PTX treatment; **=p,0.01, vs RTEF-1 o/e HMEC-1 without PTX treatment). The results were quantified based on three
experiments and are presented as mean6S.D.
doi:10.1371/journal.pone.0088143.g004
RTEF-1 Up-Regulates Edg-1 in Endothelial Cells
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e88143agents capable of intervening endothelial angiogenesis through
RTEF-1 during relevant pathophysiological events.
Supporting Information
Figure S1 DNA microarray of RTEF-1 gene knockdown
by RTEF-1 siRNA in HUVEC. Compared to negative control
siRNA, knockdown of endogenous RTEF-1 by three different
duplexes of RTEF-1 siRNA in HUVEC decreased Edg-1 gene
expression. Data was analyzed by Ingenuity Pathway Analysis
software (Ingenuity System, Redwood City, CA).
(TIFF)
Figure S2 Cx43 (A) and Edg-1 (B) mRNA in RTEF-1 o/e
and control HMEC-1s in 6 h and 24 h Matrigel. Total
RNA was extracted from cell lysates obtained from dissolved cell
networks in 6 h and 24 h Matrigel. Quantitative real-time PCR
amplification was performed. The results were quantified based on
three experiments and are presented as mean6S.D. (*=p,0.05,
vs control 6 h HMEC-1; **=p,0.01, vs control 6 h HMEC-1;
#=p,0.05, vs control 24 h HMEC-1; ##=p,0.01, vs control
24 h HMEC-1).
(TIF)
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